Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lessons learned from drug trials in neurofibromatosis: A systematic review.
Dhaenens BAE, Ferner RE, Evans DG, Heimann G, Potratz C, van de Ketterij E, Kaindl AM, Hissink G, Carton C, Bakker A, Nievo M, Legius E, Oostenbrink R. Dhaenens BAE, et al. Among authors: heimann g. Eur J Med Genet. 2021 Sep;64(9):104281. doi: 10.1016/j.ejmg.2021.104281. Epub 2021 Jul 5. Eur J Med Genet. 2021. PMID: 34237445 Free article.
Identifying challenges in neurofibromatosis: a modified Delphi procedure.
Dhaenens BAE, Ferner RE, Bakker A, Nievo M, Evans DG, Wolkenstein P, Potratz C, Plotkin SR, Heimann G, Legius E, Oostenbrink R. Dhaenens BAE, et al. Among authors: heimann g. Eur J Hum Genet. 2021 Nov;29(11):1625-1633. doi: 10.1038/s41431-021-00892-z. Epub 2021 Apr 26. Eur J Hum Genet. 2021. PMID: 33903738 Free PMC article.
Physicochemical parameters of x-ray contrast media.
Krause W, Miklautz H, Kollenkirchen U, Heimann G. Krause W, et al. Among authors: heimann g. Invest Radiol. 1994 Jan;29(1):72-80. doi: 10.1097/00004424-199401000-00015. Invest Radiol. 1994. PMID: 8144342
Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.
Dhaenens BAE, Heimann G, Bakker A, Nievo M, Ferner RE, Evans DG, Wolkenstein P, Leubner J, Potratz C, Carton C, Iloeje U, Kirk G, Blakeley JO, Plotkin S, Fisher MJ, Kim A, Driever PH, Azizi AA, Widemann BC, Gross A, Parke T, Legius E, Oostenbrink R. Dhaenens BAE, et al. Among authors: heimann g. Neurooncol Pract. 2024 Jan 4;11(4):395-403. doi: 10.1093/nop/npae001. eCollection 2024 Aug. Neurooncol Pract. 2024. PMID: 39006526 Free PMC article.
Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates.
Gaitonde P, Huh Y, Darpo B, Ferber G, Heimann G, Li J, Lu K, Sebastien B, Tsai K, Riley S. Gaitonde P, et al. Among authors: heimann g. J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):617-626. doi: 10.1007/s10928-019-09662-3. Epub 2019 Oct 30. J Pharmacokinet Pharmacodyn. 2019. PMID: 31667657
124 results